Thanks for the link to the interview. One takeaway is the reference by the CEO to getting a lot of interest in AD-214's novel mode of action in IPF. The point is made that Pharma recognise IPF is a complex disease requiring multiple therapeutic shots on goal.
Getting a lot of interest from whom? Its probably not ASX investors so the interest may be coming from prospective Pharma partners. The de-risking of AdAlta by virtue of its move into the clinic while simultaneously getting a lot of interest provides a strong rationale for buying into the story while 1AD is sitting below a MC of $20m.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.782M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 8258466 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 15452546 | 18 |
View Market Depth
| Last trade - 11.16am 01/08/2025 (20 minute delay) ? |
| 1AD (ASX) Chart |
Day chart unavailable